Journal Club - Tirzepatide may lead weight loss of up to 23 percent in obese people
Recent data from SURMOUNT-1 clinical trial showed that tirzepatide achieved superior weight loss compared to a placebo in obese/overweight individuals at 72 weeks of treatment. According to the findings, the individuals lost up to 22.2% of their body weight (52 lb.).
Tirzepatide is a novel once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The results were reported by the pharmaceutical company Eli Lilly and Company.
For more details check out the full story on the link below:
Tirzepatide May Lead Weight Loss Of Up To 23 Percent In Obese People: SURMOUNT-1 Trial
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd